GleamWall
中文EN

PDSB PDS Biotechnology Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1472091 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-281.4%
ROA-121.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.62x
Interest coverage-3.52x

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-49.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$19.03M$22.57M
SG&A expense$12.52M$13.76M
Operating income-$31.54M-$36.32M
Interest expense$5.34M$4.67M
Pretax income-$35.67M-$38.48M
Income tax-$1.17M-$869,169
Net income-$34.50M-$37.61M
EBITDA-$31.52M-$36.30M
EPS (basic)-0.74-1.03
EPS (diluted)-0.74-1.03
Weighted avg. shares (diluted)46.38M36.45M
Balance sheet
Cash & equivalents$26.71M$41.69M
Current assets$28.25M$45.05M
PP&E, net$120,184$142,020
Total assets$30.49M$45.36M
Current liabilities$9.48M$17.09M
Total liabilities$21.24M$26.35M
Shareholders' equity$9.25M$19.00M
Shares outstanding54.88M37.99M
Cash flow statement
Operating cash flow-$27.75M-$35.03M
Capital expenditure$0$29,000
Free cash flow-$27.75M-$35.06M
Investing cash flow$0-$29,000
Financing cash flow$12.77M$20.19M
Depreciation & amortization$21,836$21,112
Stock-based compensation$4.11M$6.85M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.